Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Taking specialist clinics into community nursing homes
Objective: Evaluate the effectiveness of delivering specialist Parkinson's care in community care home settings. Background: Our drive to improve older people's care has led to…Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial
Objective: 54 patients with idiopathic Parkinson's disease and freezing of gait resistant to subthalamic nucleus stimulation and dopaminergic medication will be included into this German-wide…DBS targeting: Validation of 3T MR image guided targeting using post-mortem 17T MR microscopy
Objective: This work helps validate the utility of direct targeting using 3T T1 inverted sequences with atlas application during planning for DBS electrode placement. We…Role of contact polarity on therapeutic impedances at two deep brain stimulation (DBS) targets
Objective: To demonstrate the role of contact polarity on therapeutic impedances at two DBS targets. Background: Neuromodulation with DBS is an established therapy for medically…A prospective study of patients’ expectations in subthalamic nucleus deep brain stimulation for Parkinson’s disease
Objective: To prospectively assess the long-term outcome of subthalamic nucleus (STN) deep brain stimulation (DBS) and the relationship with patients' expectations and satisfaction. Background: Subthalamic…Cognitive change following deep brain stimulation in patients with movement disorders
Objective: To assess the degree and pattern of cognitive changes following Deep Brain Stimulation (DBS) in patients with Parkinson's disease (PD), Dystonia and Essential Tremor…Mild Parkinsonian signs and TIA/stroke
Objective: We aimed to determine if MPS increases TIA/stroke risk. Background: Mild Parkinsonian signs (MPS) are a syndrome of mild basal ganglia dysfunction characterized by…
- « Previous Page
- 1
- …
- 333
- 334
- 335
- 336
- 337
- …
- 388
- Next Page »